BPC-157 vs CJC-1295
Body Protection Compound · GHRH Analog
Here is how these two compounds compare, based on published research, not marketing claims.
BPC-157
A tissue repair peptide studied for tendons, gut lining, and wound healing through local angiogenesis and growth factor signaling at injury sites.
CJC-1295
A GHRH analog that tells the pituitary gland to produce more growth hormone; the DAC version extends activity to days rather than minutes.
BPC-157
212 studies
4 human trials
Not FDA-Approved
CJC-1295
27 studies
2 human trials
Not FDA-Approved
What it does
BPC-157
In animal studies, drives new blood vessel formation at injury sites, one of the body's main repair signals in damaged tissue. A short peptide fragment originally isolated from human stomach juice that, in rodent models, ramps up production of growth factors involved in healing (VEGF, EGF, FGF). The angiogenic effect documented in those animal studies is what underlies the recovery claims that made BPC-157 prominent in athletic and post-surgical contexts. Published human evidence remains essentially absent.
CJC-1295
Stretches a growth hormone signal that normally lasts minutes into one that lasts days. A small chemistry change attaches the molecule to albumin, a protein already circulating in the blood, which protects it from being broken down. In the published research, that translates to a half-life of roughly six to eight days, compared with minutes for the body's native GHRH.
How it works
BPC-157
A copy of a small protein the body naturally makes in the stomach. It works by turning up three repair signals (VEGF, EGF, FGF) that tell the body to build new blood vessels. It also nudges the nitric oxide system, which controls blood flow and inflammation. In animal research, the result is the body's own repair process running faster.
CJC-1295
A modified version of the body's natural growth hormone signal. The modification makes it resist breakdown, so it stays active longer in the bloodstream.
How often
BPC-157
In studies, given as a daily shot under the skin, usually for several weeks at a time. Some studies have looked at oral forms specifically for gut work.
CJC-1295
In Phase I/II trials, CJC-1295 with DAC was given as a subcutaneous injection once or twice per week. The DAC modification (drug affinity complex) extends the active window to several days, which is what allows the once-or-twice-weekly schedule rather than daily injection.
How strong
BPC-157
Local. The action concentrates at the injury rather than spreading body-wide.
CJC-1295
Stronger and more sustained. A bigger growth hormone pulse that lasts longer.
Main tradeoff
BPC-157
Strong animal data on tendons and gut healing. Human studies are thin. And one quirk: most of the published research traces back to a single research group, which limits how independent the findings are.
CJC-1295
Less pulsatile than the body's natural rhythm. Side effects, if they happen, stick around longer because the drug stays active longer.
Best for
BPC-157
- Research on a specific local injury: tendons, ligaments, or gut lining
- Research targeting one site rather than a body-wide effect
- Research using daily subcutaneous injection
CJC-1295
- People who want fewer injections per week
- People who've plateaued on Sermorelin
- Anyone planning to stack with Ipamorelin (a popular combination because the two work through different receptors and amplify each other)
How to choose
A good fit for BPC-157
- Research on a specific local tissue injury: tendons, ligaments, gut lining, or wound healing
- Research targeting repair mechanisms at the injury site rather than systemic hormone elevation
- Research contexts where growth hormone modulation is not the goal
A good fit for CJC-1295
- Research on growth hormone optimization, body composition, or IGF-1 elevation
- Research targeting systemic hormone signaling through the pituitary
- Research comparing sustained (DAC) versus pulsatile (no-DAC) GH elevation patterns
Consider both across time
BPC-157 and CJC-1295 target entirely different biological systems. BPC-157 promotes tissue repair through local growth factor signaling and blood vessel formation at injury sites. CJC-1295 elevates growth hormone systemically through pituitary stimulation. They are not interchangeable for the same research goal; the comparison exists because both appear in peptide research protocols, not because they serve the same biological purpose. Some research protocols combine them to target different systems simultaneously, but no controlled study of the combination has been published.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- Tissue Repair
- Tissue Repair connects to NO System Modulation
- NO System Modulation upregulates VEGF / EGF / FGF
- VEGF / EGF / FGF connects to Blood Vessel Formation
- Blood Vessel Formation connects to Nutrient Delivery
- GHRH Receptor
- GHRH Receptor activates GHRH Signaling
- GHRH Signaling connects to Anterior Pituitary
- Anterior Pituitary connects to Growth Hormone Release
- Growth Hormone Release connects to IGF-1 Elevation
BPC-157 increases growth factors (VEGF, EGF, FGF) that signal the body to build new blood vessels at the injury site.
CJC-1295 mimics GHRH to tell the pituitary gland to release growth hormone; the DAC modification extends activity from minutes to days.
Research Evidence
BPC-157 has the larger evidence base with over 200 published studies, including two human pilot trials from 2024 to 2025. The research is concentrated in tissue repair: tendons, gut mucosa, and wound healing, primarily from animal models. CJC-1295 has approximately 27 published studies, mostly pharmacokinetic data characterizing how the compound elevates growth hormone in humans. For tissue repair research, BPC-157 has significantly more relevant published data. For growth hormone research, CJC-1295 is the relevant compound, though sermorelin has the deeper clinical history in that class.
- 1.
For specific tissue injury (tendon, gut, muscle), BPC-157 has directly relevant research.
- 2.
For growth hormone optimization and body composition. CJC-1295 is the appropriate compound.
- 3.
For post-injury recovery with GH support, some practitioners combine them, targeting different systems.
- 4.
These are not interchangeable. Choosing one over the other depends entirely on the goal.
Key Limitations
- •No head-to-head comparison exists.
- •They target different biological systems, making direct comparison limited.
- •Neither has Phase III clinical trial data.
- •Combining them is common in practice but unstudied in controlled research.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
BPC-157
"BPC-157 healed my gut issues in two weeks"
Plausible but unproven in humans
"BPC-157 fixed my tendon injury faster than anything"
Plausible but unproven in humans
"BPC-157 is completely safe with no side effects"
Insufficient evidence
CJC-1295
"CJC-1295 with DAC gives you sustained growth hormone elevation for days"
Supported by published data
"Stacking CJC-1295 with ipamorelin is the gold standard for GH optimization"
Plausible but unproven
"It made me retain water and feel bloated"
Supported by published data
Safety Comparison
BPC-157 has more published safety data overall, with no serious adverse events reported in the available human pilot studies. CJC-1295 has fewer human studies but no serious safety signals; reported side effects include water retention, numbness, and injection site reactions. Neither compound is FDA-approved. Neither has long-term post-marketing surveillance data. Compounded versions of either peptide sold in research-peptide markets are not FDA-regulated and may carry purity, potency, or contamination risks that the FDA-approved supply chain protects against.
BPC-157
Extensive animal safety data. Two human pilot studies (2024-2025) with no serious adverse events. Not FDA-approved.
CJC-1295
Limited but favorable human safety data. Side effects include water retention, numbness, and injection site reactions.
What the Research Suggests
These are not competing compounds. BPC-157 for tissue repair. CJC-1295 for growth hormone. The comparison exists because both appear in peptide protocols, not because they serve the same purpose.